Phreesia, Inc.

NYSE:PHR

Medical - Healthcare Information Services

Healthcare
$12.26 +0.80%

+$0.08 today

Market cap
$760.99M
Beta
0.88
P/E (TTM)
62.6
EPS (TTM)
$0.15
52W Low $7.77High $32.76

Volume 0.86M

Average 1.97M

PHR Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Phreesia, Inc.NYSE: PHR

Investing Cash Flow · Q1 FY2027 · quarter ended Apr 2026

Investing cash flow turns positive

Q1 FY2027 investing cash flow was $4.8M, compared with -$7.39M a year earlier. Trailing-twelve-month investing cash flow was -$149.69M. Over 3 fiscal years it compounded at +83.5% a year.

Context

  • Investing cash flow amounted to 33.7% of revenue in FY2026, up 27.9 pp from a year earlier.
  • Investing cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2026 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly investing cash flow holds near $4.8M or moves back toward the trailing-twelve-month quarterly average of -$37.42M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
$4.8M+103.4% QoQ
Last fiscal yearJan 2026
-$161.88M+572.0% YoY
LTMApr 2026
-$149.69M+474.9% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+165.0%——
1 year+572.0%——
3-year CAGR+83.5%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2026
(161.88M) USD
Year-over-year change
-572.0%

Investing Cash Flow vs competitors

How PHR compares with its peers on the latest reported figures

  • PHR's LTM Apr 2026 investing cash flow of $149.69M is the 4th largest of the 11 companies compared; the peer median is $36.88M.
  • Its year-over-year change of +474.9% is the 2nd highest of 11, against a peer median of +23.1%.
  • Investing cash flow amounts to 30.2% of revenue for PHR, versus a peer median of 9.3%.
PHR Competitors Peer median
Investing Cash Flow for PHR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$451.5M +214.9%—66.9%
SDGRSchrödinger, Inc.LTM Sep 2026$180.57M +1712.0%-13.7%67.1%
TDOCTeladoc Health, Inc.LTM Mar 2026$179.26M -15.4%+16.6%7.1%
PHRPhreesia, Inc.LTM Apr 2026$149.69M +474.9%+83.5%30.2%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$89.73M -11.7%-17.1%11.4%
OMCLOmnicell, Inc.LTM Mar 2026$60.49M +7.7%+1.0%4.9%
BLFSBioLife Solutions, Inc.LTM Mar 2026$46.19M -247.4%+7.2%46.3%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$38.33M +94.5%—45.8%
NEOGNeogen CorporationLTM Aug 2026$35.42M -210.0%-29.5%4.0%
ESTAEstablishment Labs Holdings Inc.LTM Sep 2026$9.95M +38.6%-41.3%3.8%
OMDAOmada HealthLTM Mar 2026$6.14M +41.8%+28.9%2.2%
Peer median (excluding PHR) $36.88M+23.1%-6.4%9.3%

Competitors are the stored peer set for PHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jan 2022
FY2023
Jan 2023
FY2024
Jan 2024
FY2025
Jan 2025
FY2026
Jan 2026
Net Income(118.16M)(176.15M)(136.89M)(58.53M)2.31M
Depreciation & Amortization21.3M25.3M29.49M27.89M31.45M
Deferred Income Tax143K434K228K214K(13.27M)
Stock-Based Compensation36.14M58.78M71.7M66.98M67.45M
Change in Working Capital(18.57M)(3.86M)(1.64M)(6.49M)(14.09M)
Accounts Receivables(10.22M)(11.13M)(11.21M)(8.81M)(10.15M)
Inventory00000
Accounts Payables2.88M4.77M(1.99M)(3.23M)5.26M
Other Working Capital(11.24M)2.5M11.56M5.55M(9.2M)
Other Non-Cash Items4.43M5.37M4.73M2.33M4.96M
Operating Cash Flow(74.71M)(90.12M)(32.38M)32.38M78.81M
Capital Expenditures(30.81M)(26.2M)(25.1M)(24.09M)(11.1M)
Acquisitions (Net)(34.42M)0(14.57M)0(153.19M)
Purchases of Investments000015.71M
Sales of Investments00000
Other Investing Activities(12.39M)(21.47M)(19.29M)(15.38M)(13.3M)
Investing Cash Flow(65.23M)(26.2M)(39.67M)(24.09M)(161.88M)
Debt Repayment(4.27M)(5.95M)(6.78M)(7.81M)83.18M
Common Stock Issued245.81M4.92M03.93M3.83M
Common Stock Repurchased(9M)(19.38M)(12.18M)00
Dividends Paid00000
Other Financing Activities2.42M(397K)1.84M(7.61M)(14.15M)
Financing Cash Flow234.97M(20.8M)(17.12M)(11.49M)72.85M
Effect of Forex Changes000(106K)(176K)
Net Change in Cash95.03M(137.13M)(89.16M)(3.3M)(10.39M)
Free Cash Flow(105.52M)(116.33M)(57.48M)8.29M67.71M

Phreesia, Inc.

NYSE:PHR

Intrinsic Alpha fair value

Locked

Current Price

$12.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.